VBI Vaccines Inc - VBIV Total Company Value-to-Revenue Ratio

Public company logo of VBI Vaccines, Inc. (VBIV)

VBI Vaccines Inc. (VBIV) maintains flexibility through the outsourcing of production and testing, which minimizes capital expenditures. This chart visualizes this approach via the company's EV-to-revenue ratio, while determines the latest valuation metric. Stability is bolstered by a diversified portfolio of oncology and hepatitis vaccines, which mitigates risks. Meanwhile, current revenues from the core drug require cost optimization due to market maturity.

vbivaccines.com - VBIV Company Value to Revenue (period 07/04/2022 - 11/20/2026)

VBI Vaccines - analytical breakdowns and key metrics (VBIV)

- share price and expert price forecast:
- money and cash flow information:
Fundamental company valuation:VBI Vaccines Inc.
Mass-produced product of vbivaccines.com

This indicator compares the total enterprise value, including debt, to sales volume, allowing investors to filter out speculative noise from genuine fundamental value growth. By analyzing the EV/Revenue multiple, an investor can track the asset's revaluation speed, which is critical for VBI Vaccines Inc. (VBIV), where massive R&D expenditures transition into ultra-high margins during mass vaccine production.